{"id":512952,"date":"2021-07-14T09:03:41","date_gmt":"2021-07-14T13:03:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/"},"modified":"2021-07-14T09:03:41","modified_gmt":"2021-07-14T13:03:41","slug":"auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/","title":{"rendered":"Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        \n      <\/p>\n<ul>\n<li>Bentrio\u2122 formulation well tolerated <em>in vitro<\/em> on human nasal epithelium<\/li>\n<li style=\"text-align:justify\">Up to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controls<\/li>\n<li style=\"text-align:justify\">Viral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection<\/li>\n<\/ul>\n<p align=\"justify\">Hamilton, Bermuda, July 14, 2021 \u2013 Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio\u2122 (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe <em>in vitro<\/em>, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation. The manuscript describing these preclinical data is available on a preprint server at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ybMiWNED1E5xfRF2OdKOGy4EfcklmxmHZiw9l6up6EkO6W0l6i3tfWGgvfJxEPcdPjeSpCOLtZ3rY--d7DniX18-mWk1fAG3C6-ZAJHGsd1dfp9pGpG01zM0LOujfPMG3eQ9lKDBLuz9Fi2lOWjGM8KS1LGNH8DK2N8swAG504L9qb1umXhBN95qFQBwnL2w\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.biorxiv.org\/content\/10.1101\/2021.07.12.452021v1<\/a> and will undergo scientific peer-review for potential publication.<\/p>\n<p align=\"justify\">\u201cThese data provide strong evidence for Bentrio\u2019s potential to help reduce the risk of SARS-CoV-2 infection of human mucosal cells when used preventatively and to decelerate its course when used shortly after its onset\u201c, commented Thomas Meyer, Auris Medical\u2019s founder, Chairman and CEO. \u201cRecently published clinical data from an independent research group show that targeting the nasal mucosa during the early stage of Covid-19 is an ideal strategy for preventing the propagation of SARS-CoV-2.<sup>1<\/sup> We look forward to the imminent start of the market roll-out of our Bentrio nasal spray to help address this current pandemic with a novel drug-free means for self-protection.\u201d<\/p>\n<p align=\"justify\">The preclinical studies were performed in a well-established model of reconstituted nasal epithelium from human donors (MucilAir\u2122), which provides testing conditions that tend to be more challenging than real-life conditions in the human nose. AM-301 was studied to determine its compatibility with MucilAir\u2122, its efficacy in preventing MucilAir\u2122 from being infected by SARS-CoV-2, and its ability to mitigate an established infection in MucilAir\u2122 without any previous treatment. First, AM-301 had no detrimental effects on MucilAir\u2122 inserts despite repeated application over 4 days: measures of tight junction integrity and cytotoxicity support Bentrio\u2019s safety and did not show any significant difference between treated and control cultures. An expected finding was that the ciliary beat frequency was slightly reduced due to the viscosity of the formulation.<\/p>\n<p align=\"justify\">Prophylactic treatment with AM-301 was protective against SARS-CoV-2 infection, as daily application of the product starting 10 minutes prior to inoculation led to a 2-log (99%) reduction in viral titer (Tissue Culture Infectious Dose; TCID50) by Day 4 compared to controls. Inserts that received the product daily, starting 24 or 30 h after viral infection, also had a lower viral titer, corresponding to a 12- or 14-fold lower TCID50 at the end of the treatment. In a linear-effects mixed model with log-transformed data, the time profile of SARS-CoV-2 infection was significantly decelerated compared to controls both in case of prophylactic treatment (t=5.49; p&lt;0.001) and in case of mitigation treatment starting 24 or 30 h post infection (t=3.68; p&lt;0.01).<\/p>\n<p>As recently announced, Auris Medical\u2019s affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio\u2122 by launching it in Germany. Bentrio\u2122 will shortly become available through selected online pharmacies; over the coming months, market coverage will be expanded progressively through additional distribution channels and in further countries.<\/p>\n<p align=\"justify\">\n        <strong>About<\/strong><br \/>\n        <strong>Bentrio<\/strong><br \/>\n        <strong>\u2122<\/strong>\n      <\/p>\n<p align=\"justify\">Bentrio\u2122 (AM-301) is a drug-free nasal spray for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio\u2122 forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio\u2122 was shown to reduce the infectious viral load by more than 99% when used for prevention. Further, Bentrio\u2122 was effective in slowing the growth of the viral titer when treatment started only 24 or 30 hours after infection. In allergy, a clinical investigation in a pollen challenge chamber demonstrated a significant reduction in the main symptoms of allergic rhinitis with the protective effect setting in rapidly and lasting for 4 hours.<\/p>\n<p align=\"justify\">\n        <strong>About Auris Medical<\/strong>\n      <\/p>\n<p align=\"justify\">Auris Medical is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore\u2122 \/ SemaPhore\u2122 platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio\u2122; pre-commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen\u00ae and Sonsuvi\u00ae, Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol \u201cEARS.\u201d The Company will change its name to \u201cAltamira Therapeutics Ltd.\u201d and its ticker symbol to \u201cCYTO\u201d, subject to approval by a Special General Meeting of shareholders to be held on July 21, 2021.<\/p>\n<p align=\"justify\">\n        <strong>Forward-looking Statements <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>This press release may contain statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as \u201cmay\u201d, \u201cmight\u201d, \u201cwill\u201d, \u201cshould\u201d, \u201cexpects\u201d, \u201cplans\u201d, \u201canticipates\u201d, \u201cbelieves\u201d, \u201cestimates\u201d, \u201cpredicts\u201d, \u201cprojects\u201d, \u201cpotential\u201d, \u201coutlook\u201d or \u201ccontinue\u201d, or the negative of these terms or other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, <\/em><br \/>\n        <em>the approval and timing of commercialization of AM-301, <\/em><br \/>\n        <em>Auris Medical\u2019s need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Auris Medical\u2019s product candidates, the clinical utility of Auris Medical\u2019s product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical\u2019s intellectual property position and Auris Medical\u2019s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical\u2019s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption \u201cRisk Factors\u201d in Auris Medical\u2019s Annual Report on Form 20-F for the year ended December 31, 2020, and in Auris Medical&#8217;s other filings with the SEC, which are available free of charge on the Securities Exchange Commission&#8217;s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Auris Medical or to persons acting on behalf of Auris Medical are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.<\/em>\n      <\/p>\n<p>\n        <strong>Investor contact:<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DXpxCNffFylLGrevKk0ZxYGoZuLDIVZigGFmOUa6NBtA8uEYATU310ZdeT7tRV3g2hfTmHiwemuDcUwx415rrel09H9_yVyYQK43YNuh50IAVlrLO2gUbEpFgsSi2mKo\" rel=\"nofollow noopener\" target=\"_blank\">investors@aurismedical.com<\/a>\u00a0\u00a0 \u00a0\u00a0<\/p>\n<hr \/>\n<p>1 Ahn JH et al. (2021), Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19, J Clin Invest. 131(13):e148517.<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDUxNjIyMSM0MDA5ODIzOTkjMjAwMDExMg==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/2094c8ec-7f4a-4452-871a-bfa43581c609\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Bentrio\u2122 formulation well tolerated in vitro on human nasal epithelium Up to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controls Viral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection Hamilton, Bermuda, July 14, 2021 \u2013 Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio\u2122 (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation. The manuscript &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-512952","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Bentrio\u2122 formulation well tolerated in vitro on human nasal epithelium Up to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controls Viral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection Hamilton, Bermuda, July 14, 2021 \u2013 Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio\u2122 (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation. The manuscript &hellip; Continue reading &quot;Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-14T13:03:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDUxNjIyMSM0MDA5ODIzOTkjMjAwMDExMg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2\",\"datePublished\":\"2021-07-14T13:03:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\\\/\"},\"wordCount\":1279,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDUxNjIyMSM0MDA5ODIzOTkjMjAwMDExMg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\\\/\",\"name\":\"Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDUxNjIyMSM0MDA5ODIzOTkjMjAwMDExMg==\",\"datePublished\":\"2021-07-14T13:03:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDUxNjIyMSM0MDA5ODIzOTkjMjAwMDExMg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDUxNjIyMSM0MDA5ODIzOTkjMjAwMDExMg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/","og_locale":"en_US","og_type":"article","og_title":"Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2 - Market Newsdesk","og_description":"Bentrio\u2122 formulation well tolerated in vitro on human nasal epithelium Up to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controls Viral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection Hamilton, Bermuda, July 14, 2021 \u2013 Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio\u2122 (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation. The manuscript &hellip; Continue reading \"Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-14T13:03:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDUxNjIyMSM0MDA5ODIzOTkjMjAwMDExMg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2","datePublished":"2021-07-14T13:03:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/"},"wordCount":1279,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDUxNjIyMSM0MDA5ODIzOTkjMjAwMDExMg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/","name":"Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDUxNjIyMSM0MDA5ODIzOTkjMjAwMDExMg==","datePublished":"2021-07-14T13:03:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDUxNjIyMSM0MDA5ODIzOTkjMjAwMDExMg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDUxNjIyMSM0MDA5ODIzOTkjMjAwMDExMg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/auris-medical-announces-publication-of-data-from-preclinical-studies-with-bentrio-nasal-spray-in-prevention-and-mitigation-of-sars-cov-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio\u2122 Nasal Spray in Prevention and Mitigation of SARS-CoV-2"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/512952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=512952"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/512952\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=512952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=512952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=512952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}